The effect of cPA on carotid intimate-media thickness progression in animal model with atherosclerosis
| Project/Area Number |
25293274
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nagasaki University (2014-2015)
Kanazawa Medical University (2013) |
|---|
Principal Investigator |
TSUKAHARA Tamotsu 長崎大学, 医歯薬学総合研究科(薬学系), 准教授 (00529943)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HANIU Hisao 信州大学, 先鋭領域融合研究群・バイオメディカル研究所, 准教授 (30252050)
MATSUDA Yoshikazu 日本薬科大学, 薬学部, 教授 (20377633)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MUROFUSHI Kimiko お茶の水女子大学, 学長 (00103557)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2015: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Keywords | 動脈硬化 / 内膜肥厚 / リゾリン脂質 / 核内受容体 / 血管内膜肥厚 / 生理活性脂質 / 動脈硬化症 / 糖尿病 |
|---|
| Outline of Final Research Achievements |
This study aimed to determine whether metabolically stabilized cPA, in the form of a carba-derivative of cPA (2ccPA), could reduce plasma cholesterol levels and affect the expression of genes related to atherosclerosis in apolipoprotein E-knockout (apoE－/－) mice. 2ccPA reduced LDL-C levels in these mice (n = 3) from 460 to 330 mg/ml, from 420 to 350 mg/ml, and 420 to 281 mg/ml under a western-type diet. 2ccPA also reduced expression of lipid metabolism-related genes, cytokines, and chemokines in ApoE-deficient mice on a high-fat diet. Taken together, these results suggest that 2ccPA governs anti-atherogenic activities in the carotid arteries of apoE-deficient mice.Thus, the results of this study raise the possibility of using cPA as a lead compound to develop new treatments that acton PPARγ; however, further investigation is required to determine the molecular mechanisms underlying the described effect of cPA.
|
Report
(4 results)
Research Products
(6 results)
